ε-Aminocaproic acid inhibition of fibrinolysis in vitro: Should the 'therapeutic' concentration be reconsidered?

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 1, 2007, Pages 35-39

  Nielsen, Vance G ^a   Cankovic, Lana ^a   Steenwyk, Brad L ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

aminocaproic acid; Coagulation; Fibrinolysis; Measurement techniques; Thrombelastography; Tissue type plasminogen activator

Indexed keywords

AMINOCAPROIC ACID; TISSUE PLASMINOGEN ACTIVATOR;

ANALYSIS OF VARIANCE; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; DATA ANALYSIS; DRUG DOSE COMPARISON; FIBRINOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; KRUSKAL WALLIS TEST; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; DOSE RESPONSE; DRUG EFFECT; FIBRINOLYTIC THERAPY; PHYSIOLOGY; PLASMA; STANDARD;

6-AMINOCAPROIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIS; HUMANS; PLASMA; REFERENCE STANDARDS; THROMBELASTOGRAPHY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33845807903     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e328010a359     Document Type: Article

References (20)

1. Alkjaersig N, Fletcher AP, Sherry S. ε-Aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem 1959; 234:832-837.
2. Ablondi FB, Hagan JJ, Philips M, De Renzo EC. Inhibition of plasmin, trypsin and the streptokinase-activated fibrinolytic system by ε-aminocaproic acid. Arch Biochem Biophys 1959; 82:153-160.
3. Daily PO, Lamphere JA, Dembitsky WP, Adamson RM, Dans NF. Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting: a randomized, prosepective, double-blind study. J Thorac Cardiovasc Surg 1994; 108:99-108.
4. Vander Salm TJ, Kaur S, Lancey RA, Okike ON, Pezzella AT, Stahl RF, et al. Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. J Thorac Cardiovasc Surg 1996; 112:1098-1107.
5. Kikura M, Levy JH, Tanaka KA, Ramsey JG. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006; 202:216-222.
6. Fremes SE, Wong BI, Lee E, Mai R, Christakis GT, McLean RF, et al. Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding. Ann Thorac Surg 1994; 58:1580-1588.
7. McNicol GP, Fletcher AP, Alkjaersig N, Sherry Sol. The absorption, distribution, and excretion of ε-aminocaproic acid following oral or intravenous administration to man. J Lab Clin Med 1962; 59:15-24.
8. Bennett-Guerrero E, Sorohan JG, Canada AT, Ayuso L, Newman MF, Reves JG, et al. ε-Aminocaproic acid plasma levels during cardiopulmonary bypass. Anesth Analg 1997; 85:248-251.
9. Butterworth J, James RL, Lin Y, Prielipp RC, Hudspeth AS. Pharmacokinetics of ε-aminocaproic acid in patients undergoing aortocoronary bypass surgery. Anesthesiology 1999; 90:1624-1635.
10. Ririe DG, James RL, O'Brien JJ, Lin YA, Bennett J, Barclay D, et al. The pharmacokinetics of ε-aminocaproic acid in children undergoing surgical repair of congenital heart defects. Anesth Analg 2002; 94:44-49.
11. Chandler WL, Velan T. Secretion of tissue plasminogen activator and plasminogen activator inhibitor 1 during cardiopulmonary bypass. Thromb Res 2003; 112:185-192.
12. Kang H, Kalnoski MH, Frederic M, Chandler WL. The kinetics of plasmin inhibition by aprotinin in vivo. Thromb Res 2005; 115:327-340.
13. Khalil PN, Ismail M, Kalmar P, von Knobelsdorff G, Marx G. Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass. Thromb Haemost 2004; 92:568-574.
14. Krishnamurti C, Vukelja SJ, Alving BM. Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis. Thromb Res 1994; 73:419-430.
15. Hocker JR, Saving KL. Fatal aortic thrombosis in a neonate during infusion of epsilon-aminocaproic acid. J Pediatr Surg 1995; 30:1490-1492.
16. Fanashawe MP, Shore-Lefferson L, Reich DL. Two cases of fatal thrombosis after aminocaproic acid therapy and deep hypothermic circulatory arrest. Anesthesiology 2001; 97:1525-1527.
17. Jackson D, Botea A, Gubenko Y, Delphin E, Bennett H. Successful intraoperative use of recombinant tissue plasmionogen activator during liver transplantation complicated by massive intracardiac/pulmonary thrombosis. Anesth Analg 2006; 102:724-728.
18. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17:75-81.
19. Nielsen VG. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 2006; 81:1720-1727.
20. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354:353-365.